Last reviewed: June 24, 2026
Last updated: June 24, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Many people wonder whether they must reach a certain weight before becoming eligible for Ozempic or semaglutide therapy. The truth is more nuanced: prescription criteria depend on BMI category, comorbidities, and metabolic risk factors—not an absolute weight cutoff. Understanding these clinical guidelines helps you determine whether GLP-1 receptor agonist treatment aligns with your health goals.
FDA Eligibility Criteria for Semaglutide Weight Loss
The FDA approved semaglutide (Ozempic, Wegovy) for chronic weight management in patients with a BMI of 30 kg/m² or higher, or those with a BMI of 27 kg/m² or greater who also have at least one weight-related condition such as type 2 diabetes, hypertension, or sleep apnea. This framework means two people of different weights might both qualify, depending on their metabolic health profile. Your actual body weight matters less than your BMI category and overall health status.
PlexusDx evaluates your eligibility through a comprehensive health intake that captures your BMI, medical history, and current medications. Licensed clinicians then determine whether semaglutide aligns with your specific situation, ensuring treatment is both safe and effective. This personalized approach differs from simply checking a weight threshold.
BMI vs. Body Weight: What Actually Matters
Body Mass Index (BMI) is calculated by dividing your weight in kilograms by your height in meters squared. A BMI of 30 or above is classified as obese, while 25–29.9 is classified as overweight. However, BMI is one tool among many—muscle mass, bone density, age, and ethnicity can all affect how BMI relates to actual health risk. Two people weighing the same may have different BMIs based on height, and two people with identical BMIs may have vastly different health profiles.
When considering semaglutide therapy, clinicians look beyond the BMI number to assess insulin resistance, blood sugar control, cardiovascular risk, and inflammatory markers. This holistic view helps identify whether GLP-1 treatment will address your underlying metabolic dysfunction, not just reduce your scale reading.
Medical Conditions That Lower the BMI Threshold
If you have type 2 diabetes, prediabetes, hypertension, obstructive sleep apnea, or established cardiovascular disease, you may qualify for semaglutide at a BMI as low as 27 kg/m². This lower threshold reflects FDA recognition that these conditions amplify weight-related health risks. Many patients with BMI 27–29 who carry significant metabolic burden benefit substantially from GLP-1 therapy before reaching a BMI of 30.
Metabolic syndrome—a cluster of high blood sugar, high blood pressure, high triglycerides, and abdominal fat distribution—is another key factor. Even if your BMI sits just above 25, evidence of metabolic dysfunction can warrant semaglutide consideration. PlexusDx clinicians assess these interconnected markers during intake to match you with the right treatment approach.
How PlexusDx Determines Your Semaglutide Candidacy
PlexusDx starts with a detailed health questionnaire, vital measurements, and a review of your recent labs if available. This information feeds into a clinical decision framework that considers your BMI, comorbidities, medication interactions, kidney and liver function, and personal weight-loss history. Rather than applying a one-size-fits-all weight threshold, PlexusDx tailors eligibility assessment to your unique physiology and goals.
After your initial consultation, PlexusDx can offer compounded semaglutide injection beginning at $149 per month—a flat rate regardless of your dose level, because your dose may need to go up, but your price won't. This pricing transparency makes precision GLP-1 therapy accessible without surprise cost escalations. For patients wanting deeper metabolic insight, the optional Precision Peptide Genetic Test ($99 add-on after the first month) maps your response to 14 peptide pathways, revealing whether your GLP1R and GIPR variants predict stronger or more modest semaglutide response.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Do I need to weigh a specific amount to get prescribed semaglutide?
No. Semaglutide eligibility is determined by BMI category (30+, or 27+ with weight-related conditions), not an absolute weight number. Two people of different body weights might both qualify if their BMI and health profile support it. PlexusDx clinicians assess your entire metabolic picture during intake.
What if my BMI is 28 and I have prediabetes—am I eligible?
Yes. Prediabetes is a weight-related condition that qualifies you for semaglutide at a BMI as low as 27. PlexusDx evaluates your fasting glucose, HbA1c, and insulin resistance markers to confirm candidacy and determine whether GLP-1 therapy can help reverse metabolic dysfunction before progression to type 2 diabetes.
How much does semaglutide cost at PlexusDx, and does price change with dose?
Compounded semaglutide injection at PlexusDx starts at $149 per month on a flat-rate basis—your price remains the same whether your dose increases over time. PlexusDx also accepts HSA and FSA funds, making treatment more accessible without insurance requirements.
Is weight loss guaranteed once I meet the BMI threshold for semaglutide?
Semaglutide significantly reduces appetite and improves blood sugar control, but individual results vary based on adherence, lifestyle, genetics, and underlying metabolism. Clinical trials show an average weight loss of 15% over 68 weeks, though some patients achieve more or less. PlexusDx's optional Precision Peptide Genetic Test can reveal whether your GLP1R and MC4R variants predict stronger GLP-1 responsiveness.
What is the Precision Peptide Genetic Test, and does it affect my eligibility?
The Precision Peptide Genetic Test ($99 add-on after your first month) analyzes 150+ genetic insights across 49 peptides and 14 metabolic pathways, including your GLP1R, GIPR, FTO, and MC4R variants. This test predicts your GLP-1 sensitivity and metabolic predispositions but does not override BMI-based eligibility—it personalizes your therapy after you qualify.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Does Zepbound Work as Well as Wegovy? A Comparison of Modern Weight Loss Solutions
How to Help Ozempic Nausea: Relief and Management Strategies